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Abstract 
 
The pathophysiology of chronic fatigue syndrome (CFS) remains unclear; however, 
both biological and psychological factors have been implicated in establishing or 
maintaining this condition. People with CFS report significant and disabling cognitive 
difficulties such as impaired concentration that in some cases are exacerbated by 
exposure to chemical triggers. The aim of this study was to determine if 
neuropsychological deficits in CFS are triggered by exposure to chemicals, or 
perceptions about the properties of these substances. Participants were 36 people with 
a primary diagnosis of CFS, defined according to Centers for Disease Control (CDC) 
criteria. 
 
A randomized, double-blind, placebo-controlled, crossover design was used, 
with objective assessment of neuropsychological function and participant rating of 
substance type, before and after exposure to placebo or chemical trigger. Results 
showed decrements in neuropsychological tests scores on three out of four outcome 
measures when participants rated the substance they had been exposed to as “chemi- 
cal.” No change in performance was found based on actual substance type. These 
results suggest that cognitive attributions about exposure substances in people with 
CFS may be associated with worse performance on neuropsychological tasks. In 
addition, these findings suggest that psychological interventions aimed at modifying 
substance-related cognitions may reduce some symptoms of CFS. 
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Currently, there are at least two competing models to account for chronic fatigue 
syndrome (CFS) emphasizing biological and psychological factors respectively. 
According to the biological–immune dysfunction model, CFS is considered the 
expression of an abnormal antiviral response that results in dysregulation in the 
production of cytokines. A variant on this model, the hypersensitivity model of CFS, 
suggests that people with CFS respond with “excessive or adverse physical or 
psychological reactions to a variety of stressors or substances, which might include 
drugs, vaccines, yeast, parasites, certain foods, airborne allergens, and Post-Traumatic 
Stress Disorder” (Friedberg, Dechene, McKenzie, & Fontanetta, 2000, p. 60). 
 
It is argued that immunological hypersensitivity may arise from allergies, 
neurohormonal sensitization, or limbic kindling (Friedberg et al., 2000). Alternative 
models of CFS emphasize psychological factors in the etiology of CFS. An example 
of this type of model is the cognitive–behavioral (CB) model of CFS (Prins & 
Bleijenberg, 1999). According to the CB model, people with CFS are thought to 
attribute their illness to a physical cause (which could include viral infection) and 
believe their condition will worsen with exertion. Thus patients avoid physical 
activity, thereby producing physical deconditioning and amplification of somatic 
symptoms, illness maintenance, and disability. Although it is unlikely that CFS is due 
to either biological or psychological factors alone, understanding the relative 
contribution of these variables is important to inform treatment and account for 
symptoms such as impaired neuropsychological functioning (Michiels & Cluydts, 
2001). 
 
This study was designed to compare a biological model of CFS based on a potential 
hypersensitivity trigger for immunological dysfunction with a psychological model 
for CFS focusing on attributions, with the overall aim of helping patients and 
clinicians better identify treatment options for people with CFS. To maximize the 
likelihood of observing effects, we used a design that involved exposing CFS patients 
to substances previously rated as “triggers” by them. Two hypotheses were proposed. 
First, if the hypersensitivity model of CFS with its emphasis on biological factors 
better accounts for the etiology of CFS, we expected to observe reduced performance 
on neuropsychological tests after participants were exposed to a trigger substance but 
not placebo. However, if the CB model of CFS provides a better account of this 
disorder, we expected to find a difference in performance on neuropsychological tasks 
based on “beliefs” about exposure substance and that performance would be reduced 
following exposure to substances rated as “chemical” when in fact these substances 
were neutral. 
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METHOD 
 
 
 
Participants 
 
Thirty-six adults who were admitted to a specialist unit in a private hospital for 
allergy testing participated in this study. All participants had a primary diagnosis of 
CFS based on the CDC criteria for CFS (Fukuda et al., 1994), with an etiology linked 
to chemical or food sensitivity based on participant self-report and medical opinion. 
CFS patients who report substance sensitivities have been described previously and 
have been found to report sensitivities at rates comparable to patients formally 
diagnosed with multiple chemical sensitivity (see Fiedler, Kipen, DeLuca, Kelly-
McNeil, & Natelson, 1996). 
 The average age of participants was 39 years (SD = 13.6), and the average 
number of years of education for the sample was 13.6 (SD = 2.5). Seventy-two 
percent of the sample was female, and the average full-scale IQ calculated using 
Kaufman’s Quick Tetrad (Kaufman, 1990) was 102 (SD = 11.0). Scores on the 
Depression, Anxiety, & Stress Scales ([DASS] an Australian measure of depression, 
anxiety, and stress; P. F. Lovibond, 1993 & S. H. Lovibond, 1995) suggest higher 
than average levels of depression (M = 8.8, SD = 8.9), stress (M = 11.2, SD = 10.2), 
and anxiety (M = 6.7, SD = 7.4) in this sample, compared to healthy adults of the 
same age—a finding that is not uncommon in CFS samples (DiPino & Kane, 1996; 
Joyce, Blumenthal, & Wessely, 1996; Simon, Katon, & Sparks, 1990). Approximately 
three of four people in the sample endorsed items on a self-reported complaints 
checklist indicating they had memory problems (neuropsychological symptom 
checklist; Psychological Assessment Resources, 1983). The mean response to a visual 
analog scale item assessing the degree of self-reported memory complaint was 61.82 
(SD = 21.94), which suggests mild levels of self-reported memory impairment for this 
sample overall. Finally, most people in this sample were seeking compensation from 
an insurer either from workcover or their employer. 
 
 
Design 
 
We used a randomized crossover design as illustrated in Figure 1. 
 
 
Procedure 
 
Participants were admitted to hospital to undergo controlled chemical exposure 
reactivity (ER) tests as part of routine clinical assessment. ER tests were conducted to 
assess patients’ reactions to low-level exposure to potential trigger substances. All 
patients were routinely referred for neuropsychological assessment as part of ER 
testing. 
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ER testing was carried out in a controlled environment designed to minimize chemical 
exposure. For example, water and air in the test unit were filtered to minimize 
exposure to potential trigger substances. Prior to ER testing, participants were 
exposed to various substances until a “reactive substance” (potential pathogen, e.g., 
trichlorethane) was identified. This substance was selected by an allergist (not 
involved in testing participants), based on clinical criteria and patients’ subjective 
responses to substances measured on a reactivity checklist. 
 
Nursing staff prepared two identical syringes, one containing the highly dilute 
reactive substance (chemical) and one containing placebo (distilled water). Substances 
were injected into a vaporizer and circulated in an enclosed environment in which the 
participant was seated (chamber challenge). The use of “chamber challenge” and 
provocation testing techniques to establish allergic reactivity is a well-accepted 
methodology (Selner, 1996). All substances were administered with a masking 
substance such as vanilla essence, to which participants did not react. The amount of 
substance to which participants were exposed was minute and well below Australian 
safety standards. Trained medical staff remained present to monitor and record 
participant behavior during exposure.  
 
  A double-blind procedure for conducting exposure trials was followed. 
That is, neither the testing psychologist nor the patient knew what the trial substance 
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would be, but both were aware that a chemical would be used in one trial, and a 
placebo used in the other. To prevent potential “carryover” effects from substance 
exposure, trials were conducted on separate days (1 day apart). Memory and ability 
testing was carried out immediately before and 1 hr after exposure trials in the 
patient’s room. At the end of each postexposure test session, participants were asked 
what they thought the substance had been: chemical or placebo. 
 
 
 
Materials 
 
 Participants were asked to complete neuropsychological tests before and after 
exposure to placebo and chemical (see Figure 1). Four tests were selected in 
accordance with recommended guidelines for neurotoxicity assessment (American 
Academy of Neurology, 1996; Lezak, 1995; Tiersky, Johnson, & Lange, 1997). 
Measures used assessed auditory–verbal memory (prose passages, e.g., Wechsler, 
1987); attention (digit span; e.g., Wechsler, 1981); and motor speed, coordination, and 
visuospatial ability (letter cancellation [LC; see Lezak, 1995] and Symbol Digit 
Modalities Test [SDMT; Smith, 1982]). These tests were selected to assess cognitive 
abilities considered to represent the “most prominent features of cognitive 
dysfunction” in people with CFS (Michiels & Cluydts, 2001, p. 84). Further, the 
specific measures used in this study were selected because they have been used 
previously to explore possible neurotoxic effects of chemical exposure, including 
prior use of the SDMT (e.g., Bowler, Sudia, Mergler, Harrison,&Cone, 1992), LC 
(e.g., Chopra, Gupta, & Agarwal, 1993; Moss-Morris, Petrie, Large, & Kydd, 1996), 
Digit Span (e.g., Dipino&Kane, 1996; Moss-Morris et al., 1996), and prose passages 
(e.g., Riccio, Thompson, Wilson, Morgan, & Lant, 1992; Sandman, Barron, Nackoul, 
Goldstein,&Fidler, 1993; but see Smith, Behavn, Bell, Millar,& Bakheit, 1993). 
 
 The order of test administration was selected to ensure participants alternated 
between paper-and-pencil tests and auditory–verbal tasks. To minimize practice 
effects given the repeated measures design, alternate forms were used if possible (e.g., 
the version of Digit Span from the Wechsler Adult Intelligence Scale–Revised was 
used [Wechsler, 1981] as well as a published variant [Lezak, 1995]). If no (or an 
insufficient number of) published variant(s) of the test existed, experimental variants 
were usually devised by Simon Smith (an experienced consultant neuropsychologist), 
with the exception of prose passage variants (devised by Karen Sullivan). Variants of 
measures were devised to have similar properties to standard measures (e.g., LC 
variants had the same scatter pattern and ratio of target to nontarget elements; prose 
passage variants had the same number of words and scoring elements as standard 
versions; and symbol–digit variants were devised by keying standard symbols to 
different numbers) and were administer ed in a pseudorandom manner. All tests and 
variants were administered 
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according to standardized administration and scoring procedures (e.g., LC variants 
were administered according to standard administration and scoring procedures for 
the LC task [see Lezak, 1995]). The within-participants design used for this study, 
combined with counterbalancing of the order of presentation of measures, were 
strategies undertaken to minimize effects due to the use of variants. 
 
RESULTS 
 
The results for this study are presented in two sections. First, results showing effects 
of exposure to substances are reported, followed by results based on perceptions about 
substances. An alpha level of 0.05 was used to determine statistical significance 
unless otherwise stated. 
 
Analysis of the Effect of Substance on Performance 
 
The means and standard deviations of measures used in this study are reported in 
Table 1 by exposure substance. It can be seen that means and standard deviations for 
each measure are reasonably uniform across conditions.  
 
 A two-way repeated measures analysis of variance (ANOVA) was used to 
assess the effect of exposure to substances pre- and postexposure trials. Both factors 
were within-participants with two levels each (i.e., perceived substance [placebo and 
chemical] and time [pre- or postexposure]). There were no significant Substance Time 
interactions on any of the measures. That is, scores for participant’s pre- and 
postexposure to chemicals did not differ on Digit Span, LC, prose passages, or 
SDMT. These data show a general trend toward worse performance postexposure, 
regardless of which substance was used. That is, perfor- mance did not decline when  
 
 
 
  
168 
participants were exposed to chemicals any more than when they were exposed to 
placebo. This suggests there was no difference in performance based on exposure 
substance. 
 
Analysis of the Effect of Perceptions-of-Substance on Performance 
 
The means and standard deviations of measures used in this study by perceived 
exposure substance are reported in Table 2. Table 2 shows a decrease in mean scores 
on all measures postexposure to perceived chemical substance, whereas postexposure 
scores after perceived placebo increased slightly on three measures (Digit Span, LC, 
and prose passages). Interestingly, scores on the LC task increased on average by 2 
points in the placebo condition and decreased by a similar extent in the chemical 
condition. 
 
For this analysis, perceived substance was used as a within-groups independent 
variable to test the effect of attributions about substance on performance before and 
after exposure. Using a two-way repeated measures ANOVA, results showed 
significant interactions on two out of four measures in the expected direction— that 
is, when participants thought they had been exposed to a chemical performance on 
SDMT and prose passages deteriorated. Results for the LC task did not yield a 
significant interaction effect but did show a significant perceived substance main 
effect. Inspection of descriptive statistics for LC shown in Table 3 reveals worse 
performance on average in the perceived chemical condition overall, irrespective of 
pre- and postexposure conditions. Finally, performance on Digit Span showed a trend 
in the expected direction (i.e., worse performance after perceived chemical exposure), 
although this difference was not significant. 
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 There were 14 participants who correctly identified substances on both 
occasions, and 11 participants who incorrectly identified substances. Some 
participants (n = 7) responded “don’t know” when asked to which substance they had 
been exposed  
 
 We took a conservative approach to this analysis by removing “don’t knows” 
from our data set rather than classifying these responses as wrong. When participants 
thought they had been exposed to a chemical but in fact it was placebo, performance 
deteriorated by approximately 6.5 points on the LC task. Conversely, when 
participants thought they had been exposed to placebo, when in fact it was chemical, 
scores increased by 1.7 points on this task. Although the drop in performance by those 
who thought they had been exposed to a chemical might be considered relatively 
small effect, it is nonetheless impressive given participants were in fact exposed to a 
substance that was inert. 
 
 
 
DISCUSSION 
 
 The aims of this study were twofold: first, to assess the relationship between 
neuropsychological functioning and exposure to chemical trigger substances and 
second, to explore the relationship between neuropsychological performance and 
perceptions about exposure substances.  
 
 The first hypothesis for this study was that participants’ performance on a 
range of neuropsychological tasks would be worse after exposure to chemical trigger 
substances. This hypothesis was intended to provide a test of the hypersensitivity 
model of CFS, which posits that CFS has a predominantly biological basis and that 
symptoms may be exacerbated by exposure to particular substances (Friedberg et al., 
2000). The range of cognitive abilities tested in this study were primarily selected on 
the basis of a literature review that suggested that the most consistent pattern of CFS-
related cognitive deficits were decreased processing speed, attention and 
concentration, and auditory–verbal memory  (DiPino & Kane, 1996; Keenan, 1999; 
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Moss-Morris, Petrie, Large, & Kydd, 1996; Tiersky et al., 1997). Contrary to 
expectations, we failed to show a significant decrease in performance on any of the 
tests of cognitive function we used based on substance. That is, no significant 
deterioration was noted on tests of attention and concentration (Digit Span), 
visuospatial ability and processing speed (LC and SDMT), or auditory–verbal 
memory (prose passages). 
 
 The second hypothesis for this study was that participants’ performance on a 
range of neuropsychological tasks would be worse after exposure to the substance 
they perceived as chemical. This hypothesis was intended to provide a test of the CB 
model of CFS, which posits that CFS has a predominantly psychological basis and 
that symptoms may arise from maladaptive patterns of cognitive attributions and 
behavior. Consistent with expectations, we found significant decreases in 
performance on three out of four objective tests of cognition, based on participants’ 
beliefs about exposure substance (i.e., whether they rated it chemical when in fact it 
was placebo). Specifically, significant deterioration in performance was found on 
tasks of information-processing speed (LC and SDMT) and auditory–verbal memory 
(prose passages). No significant deterioration was found on the attention task we used 
(Digit Span), although a trend in the predicted direction was apparent. 
 
The absence of a substance effect in the presence of a partial perception effect 
necessitates specific consideration of factors that may have contributed to a null 
substance effect. For example, it could be argued that substances selected for use as 
“reactive” test substances were chosen incorrectly; therefore the actual biological 
stimulus was insufficient to induce a reaction based on hypersensitivity. This 
limitation cannot be ruled out. However, as noted previously test substances were 
selected on the basis of two independent criteria: ratings by an expert allergist based 
on clinical grounds and subjective ratings of reaction by participants themselves. 
Given the rigorousness with which substances were selected, we think this 
explanation of the null effect of substance is unlikely.  
 
 Similarly, it could be argued that either participants were exposed to 
insufficient quantity of substance to induce a reaction (or that exposure time was too 
short) or that the mode of exposure (gaseous) was not an effective route of 
administration.  Although these limitations cannot be discounted, it is important to 
note that significant decreases in performance were found on tasks with this 
experimental design when substance-perception was used in data analysis. Future 
studies could explore the effect of titrated exposure, within safe exposure limits, to 
further explore this issue. In addition, future research could explore alternate routes of 
administration for test substances (including exposure effects to vapors via nonnasal 
routes; see Millqvist, Bengtsson, & Löwhagen, 1999); however, this should probably 
be done with the caveat that alternative routes of administration should be limited to 
method of exposure usually associated with triggering CFS symptoms experienced by 
the participant, which in many instances is gaseous. 
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 Overall, findings from this study support the conclusion that psychological 
factors were responsible for decrements in cognitive performance observed in this 
sample and that the actual substance to which participants were exposed was of little 
significance. That is, in this subgroup of people with CFS, psychological factors 
(attributions) appear to be more likely to determine pattern of performance on selected 
neuropsychological tests than potential biological triggers. This pattern of results is 
consistent with previous studies that have shown that psychological factors such as 
hypochondriasis (Roht et al., 1985), level of worry (e.g., McMahan & Meyer, 1995), 
or other psychological symptoms (e.g., Staudenmayer & Kramer, 1999) may be more 
strongly associated with adverse symptom report than exposure to factors thought to 
account for symptoms. Further, in studies using similar methodologies (i.e., double-
blind symptom provocation through substance challenge) similar results have been 
found (e.g., Jewett, Fein, & Greenberg, 1990; Staudenmayer, Selner, & Buhr, 1993). 
Taken together, this pattern of results suggests that rates of reported symptoms 
following placebo or active substance exposure may not differ significantly, and we 
would argue that this underscores the importance of assessing attributions about the 
substance to which participants have been exposed. Although it is compelling to 
generalize results to conclude that biological factors played no role in the 
symptomatology of participants assessed under ER test conditions in this study, it is 
more likely that there is a complex interplay between psychological and biological 
factors that trigger a response. On this point, it is worthwhile noting that CB models 
of “psychological” disorders like panic emphasize the interrelationship between 
“physical” symptoms, such as palpitations, and the psychological (or cognitive) 
attributions that may be placed on these. Indeed, in many illnesses, both psychological 
and biological factors are probably present to some extent. Future studies might look 
at assessing cognitive attributions in more detail to explore the perceived 
consequences that participants, such as ours associate with being exposed to 
chemicals. From a treatment perspective, the demonstration that psychological 
variables can have a profound effect on cognitive task performance should strengthen 
the growing evidence base supporting use of CB as a treatment for CFS. 
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